TABLE 6.
Treatment response as described in case series
| Species | N | Treatment | Surgery (including amputation) | Treatment response | Reference | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cured | Still on treatment | Amputation | Not cured or recurrenceb | Lost to follow up | Corrected cure ratea (%) | |||||
| Madurella mycetomatis | 13 | Ketoconazole (100–400 mg/day) | Unknown | 4 (30.8%) | 9 (69.2%) | 30.8 | (287) | |||
| Madurella mycetomatis | 1,242 | Ketoconazole (400–800 mg/day) | 1,242 | 321 (25.8%) | 35 (2.8%) | 215 (17.3) | 671 (54.0%) | 56.2 | (281) | |
| Madurella mycetomatis | 11 | Itraconazole (400 mg/day) | 0 | 1 (9.1%) | 10 (90.9%) | 9.1 | (288) | |||
| Madurella mycetomatis | 377 | Itraconazole (400 mg/day) | 164 | 48 (12.7%) | 306 (81.2) | 23 (6.1) | 13 | 67.6 | (282) | |
| Madurella mycetomatis or Falciformispora senegalensis | 23 | Itraconazole | 23 | 23 (100%) | 100.0 | (42) | ||||
| Madurella mycetomatis or Falciformispora senegalensis | 68 | Terbinafine (500 mg BID) | 49 | 20 (29.4) | 32 | 18 | 2 | 14 | 55.6 | (42) |
| Falciformispora species | 4 | Azoles | 3 (75%) | 1 (25%) | 1 (25%) | 2 (50%) | 25 | (136–138, 233) | ||
| Trematosphaeria grisea | 5 | Azoles | 1 | 1 (20%) | 4 (80%) | 20 | (103, 283–285) | |||
| Scedosporium species | 3 | Azoles | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3) | (286) | |||
| Fusarium species | 19 | Azoles | 6 (31.6%) | 5 (26.3%) | 1 (5.3%) | 7 (36.8%) |
6 (31.6%) | 38.5 | (140) | |
a
For the corrected cure rate, only those patients who had completed their treatment and were not lost to follow-up were included. For that, we used the following calculation: (number of cured patients)/[(total number of patients) − (number of patients under treatment) − (number of patients lost to follow-up)] × 100.
b
Not cured also includes patients who improved on treatment as they were still not cured.